i-Diagnostics Insights: TIRF Labs develops a global non-profit project described at the URL: i-Diagnostics.net, which goal is to prevent future epidemics and minimize the damage from existing diseases. We are uniquely-well positioned in the area of molecular diagnostics and our way to give back to society is to create two clusters of open source platforms that based on our patent-pending technologies TIRF Analytix and i-Diagnostics. TIRF Analytics platform, if available for ~20,000 research groups worldwide, will create a global infrastructure of precision medicine and enable swift localization of outbreaks, rapid drug screening and re-purposing of FDA-approved drugs for prophylactics and treatment of emerging diseases. We believe that for rapidly mutating pathogens re-purposing of previously FDA-approved drugs is an efficient way to prevent emerging pandemics. Several research groups worldwide have already used our TIRF Analytix platform for single molecule biology mechanistic studies, drug discovery, as well as for rapid molecular diagnostics. We envision that price-efficient TIRF Analytix will be available to all research groups worldwide and affordable i-Diagnostics devices will be available to general public. The US government has granted $4.3M for Phase I of our project. We are ready to move to Phase II to make the preventative precision diagnostics available for all.
We have supplied TIRF Analytix products and i-Diagnostics prototypes to several laboratories in the U.S. and abroad. We pledge to make TIRF Analytix and i-Diagnostics open source platforms suitable for a global infrastructure of precision medicine so that accurate diagnostics will be available to everyone. Soon after the outbreak of Corona virus and the emergence of COVID-19 epidemic, our TIRF Analytix customers discovered new, anti-COVID-19 functions of a dozen of previously FDA-approved drugs, including Hydroxychloroquine, Fenofibrate, and Ivermectin; the latter being the champion due to exceptionally low toxicity. Paradoxically, the low cost of Ivermectin turned to be the greatest obstacle of using it in the U.S. and other industrialized countries. The North India state Uttar Pradesh of 231 million people eradicated COVID-19 with Ivermectin treatment program, representing one of the greatest public health achievements in history. It was kept a global secret.
We welcome you to share your opinions and ideas about emerging and propagating pandemics. The COVID-19 crisis has demonstrated that we need a global infrastructure, which would help to prevent, localize and combat pandemics. TIRF Labs’ team is committed to make accurate diagnostics available to everyone. Scientific and technological capabilities for efficient management of pandemics already exist. Scientists and medical professionals have outlined the necessary measures on COVID-19 in the Great Barrington Declaration and in the Open Letter of Belgian Medical Doctors. The same or similar measures and approaches apply to future pandemics.
In 2019-2020 our customers used our TIRF microarray technology to discover and re-purpose FDA-approved old drugs to prevent and cure COVID-19. Dozens of re-purposed drugs have been found efficient for prophylactics and treatment of COVID19, including Ivermectin, Fenofibrate, and Hydroxycholoroquine. I, Dr. Alexander Asanov, used some of them to keep traveling amidst COVID-19 pandemic. Ivermectin is less toxic than aspirin and appears to be the absolute champion – the global solution for COVID-19, most of other RNA viruses, and some of DNA viruses. It is also efficient against Tuberculosis, some other microbial pathogens, certain types of cancer, inflammation, etc, etc. Ivermectin was discovered in the late 1970s. In 2015 The Nobel Prize in Physiology or Medicine was awarded to Drs. William C. Campbell and Satoshi Ōmura for their discoveries of Ivermectin.
Unfortunately, there is a large gap between science, mass media and decision-making politicians. Safety of biological materials for human use, including vaccines and drugs, must be the highest priority in all circumstances. If adverse side-effects and multiple deaths are reported, the biological material must be removed from the market, without any delay.
Vaccines vs. Re-purposing Existing Medicine. The development of new vaccines, even if the pathogen does not mutate, in principle, cannot be fast. Typically, it takes several years. Long-term side effects of genetic materials injected into human body are impossible to predict. Therefore, alternative approach – re-purposing of previously approved drugs (approved for other purposes) to combat new pathogens – appears to be a productive method, which has proven its efficiency in numerous instances over several decades. In the beginning of COVID-19 pandemic dozens of FDA-approved drugs have been found efficient for prophylactics and treatment of COVID-19. Ivermectin, a potent a potent antiparasitic agent was found to be efficient for for prophylaxis and treatment of COVID-19, as well as most of other RNA viruses, some DNA viruses, and even bacterial infections. The State of Nebraska was the first U.S. state, which approved Ivermectin as COVID-19 treatment. Dr. Ben Carson showed that despite the lack of so-called “gold standard” double-blind studies, we now effectively know that early (off-label) use of the anti-parasite drug Ivermectin can have a significant effect on reducing COVID mortality — especially when used in conjunction with other substances like azithromycin, zinc, and Vitamin D. Running a double-blind study requires large amount of funds — the kind of money that only a new, patented drug–maker could afford, in hopes of selling a high-priced remedy to millions of consumers. Repurposing off-patent drugs like Ivermectin does not yield the kind of profits that would be necessary to pay back the cost of double-blind studies. So this appears to be the main obstacle for using safe and efficient Nobel-Prize-awarded inexpensive substance – Ivermectin. A remarkable paper has been published on the data explaining “Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?”
Ivermectin
![](https://i0.wp.com/tirf-labs.com/wp-content/uploads/2021/11/Ivermectin.jpg?resize=407%2C405&ssl=1)
Ivermectin successfully went through numerous clinical trials for prophylaxis and treatment of COVID-19 [https://clinicaltrials.gov/]. See also videos by Dr. John Campbell on YouTube and references to recent original articles that he provided. Repurposing of old drugs for new applications is a common practice in medicine. For example, doctors are giving infants and babies the anti-ED drug Viagra to save them from a life-threatening lung condition. In 2020 the groundbreaking paper on anti-viral use of Ivermectin was published: “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” Dr. Pierre Kory, et alter wrote: “In March 2020, an expert panel called the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik with the goal of continuously reviewing the rapidly emerging basic science, translational, and clinical data in order to gain insight into and develop a treatment protocol for, COVID-19. At the same time, many centers and groups employed a multitude of novel therapeutic agents empirically and within clinical trials, often during inappropriate time points during this now well-described multi-phase disease. Either as a result of these frequent trial design failures or due to the lack of sufficient anti-viral or anti-inflammatory properties, nearly all trialed agents have proven ineffective in reducing the mortality of COVID-19.
Based on a recent series of negative published therapeutic trial results, in particular the SOLIDARITY trial, this virtually eliminates any treatment role for remdesivir, hydroxychloroquine, lopinavir/ritonavir, interferon, convalescent plasma, tocilizumab, and mono-clonal antibody therapy. [Advances] Despite the growing list of failed therapeutics in COVID-19, the FLCCC recently discovered that ivermectin, an anti-parasitic medicine, has highly potent real-world, anti-viral, and anti-inflammatory properties against SARS-CoV-2 and COVID-19.
![](https://i0.wp.com/tirf-labs.com/wp-content/uploads/2021/11/375px-Respiratory_system_complete_en.svg_.png?resize=375%2C399&ssl=1)
This conclusion is based on the increasing study results reporting effectiveness, not only within in-vitro and animal models, but also in numerous clinical trials from centers and countries around the world. Repeated, consistent, large magnitude improvements in clinical outcomes have now been reported when Ivermectin is used not only as a prophylactic agent but also in mild, moderate, and even severe disease states from multiple, large, randomized and observational controlled trials.
Further, data showing impacts on population wide health outcomes have resulted from multiple large “natural experiments” that appear to have occurred when various regional health ministries and governmental authorities within South American countries initiated “ivermectin distribution” campaigns to their citizen populations in the hopes the drug would prove effective. The tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin is proving to be a global solution to the pandemic. This is now further evidenced by the recent incorporation of Ivermectin as a prophylaxis and treatment agent for COVID-19 in the national treatment guidelines of Egypt as well as the state of Uttar Pradesh in Northern India, populated by 210 million people.”
Recent review article on Ivermectin was published by Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, de Oliveira RN, and Pena L. “Ivermectin: an award-winning drug with expected antiviral activity against COVID-19,in Journal of Controlled Release Volume 329, 10 January 2021, Pages 758-761: Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
NIH database contains 10,000+ original research papers and reviews on Ivermectin: https://pubmed.ncbi.nlm.nih.gov/?term=ivermectin
Fenofibrate, an FDA-approved anti-cholesterol drug also demonstrated efficacy against the newly emergent alpha and beta variants of SARS-CoV-2 in the recent study.
What do you think about the current pandemic? What can we do now to prevent devastating pandemics in the future? Do you think that availability of precise and accurate diagnostics for home use, similar to i-diagnostics, is critical for the current and future efforts? We would be delighted to hear from you.
Visit the website www.i-diagnostics.net to donate to our global project.
July 13, 2022
Doctor Peter A McCullough | The Pfizer Vaccine Installs DNA Into the Human Genome
The Great Reset | Explained In Their Own Words (Gates, Musk, Harari, Schwab & Grimes) https://rumble.com/v14382h-the-great-reset-explained-in-their-own-words-gates-musk-harari-schwab-and-g.html
Entire Great Reset / 4th Industrial Agenda Explained In 10 Minutes or Less: https://timetofreeamerica.com/the-great-reset-explained/
WATCH for FREE: Watch the ReAwaken America Tour Documentary for FREE Today At: https://store.thrivetimeshow.com/
Connect the Dots Between COVID-19 / The Great Reset, The Fourth Industrial Revolution, Klaus Schwab, 5G, and the RNA-Modifying COVID-19 Vaccines Agenda: https://timetofreeamerica.com/revelation
October 5, 2021
Peter McCullough, MD, MPH speaks at the 78th Annual Meeting of the Association of American Physicians and Surgeons on October 2, 2021
ABOUT DR. McCULLOUGH: Dr. McCullough is board certified in internal medicine, cardiovascular diseases, and clinical lipidology. He cares for advanced patients with common medical problems including heart and kidney disease, lipid disorders, and diabetes. He has become an expert on COVID-19 illnesses and welcomes recovered patients into his practice.
After receiving a bachelor’s degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School. He went on to complete his internal medicine residency at the University of Washington, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master’s degree in public health at the University of Michigan.
Dr. McCullough has broadly published on a range of topics in medicine with > 1000 publications and > 600 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, British Medical Journal and other top-tier journals worldwide. He is the editor-in-chief of Reviews in Cardiovascular Medicine and senior associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), and the European Medicines Agency. He has served as member or chair of data safety monitoring boards of 24 randomized clinical trials.
Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 35 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in TheHill. On November 19, 2020, Dr. McCullough testified in the US Senate Committee on Homeland Security and Governmental Affairs concerning early ambulatory treatment of high-risk patients with COVID-19. Dr. McCullough is a COVID-19 survivor himself and welcomes post-COVID-19 patients into his practice and will help them through the range of post-infection complications.
BOARD CERTIFICATIONS: Cardiovascular Disease, Advanced Lipidology, Internal Medicine
HOSPITALS: Baylor Scott & White Heart and Vascular Hospital – Dallas * Fort Worth Baylor University Medical Center
CLINIC LOCATIONS: Heart Place Baylor Heart & Vascular Hospital-BHVH
Short-term and long-term effects of the experimental gene therapy jabs
THIS IS THE VERY VERY VERY SHORT LIST
Airline and military pilots falling ill or dropping dead midflight after being vaccinated.
Last year, 400 athletes collapsing unexpectedly with heart problems , the
Covid vaccine being the greatest common denominator.
Attorney Tom Renz made worldwide headlines after disclosing explosive data from the Department of Defense DMED database at Senator Ron Johnson’s Second Opinion Hearing . DMED is the official database of the 1.4-million active-duty DoD servicemen and it showed shocking increases in medical conditions from the mRNA “vaccines” after the military demanded injections for all service members: Here are the data:
279% SPIKE in Miscarriages
487% SPIKE in Breast Cancer
1048% SPIKE in the Nervous System
155% SPIKE in Birth Defects
350% SPIKE in Male Infertility
369% SPIKE in Testicular Cancer
2181% SPIKE in Hypertension
664% SPIKE in Malignant Neoplasms
680% SPIKE in Multiple Sclerosis
551% SPIKE in Guillain-Barre Syndrome
468% SPIKE in Pulmonary Embolism
302% SPIKE in Tachycardia
452% SPIKE in Migraines
471% SPIKE in Female Infertility
437% SPIKE in Ovarian Dysfunction
269% SPIKE in Myocardial infarction
291% SPIKE in Bell’s palsy
467% SPIKE in Pulmonary Embolism
Links to Dr. Steven Hotze website:
Video with Transcript:
https://www.hotzehwc.com/2021/02/dr-hotze-on-the-dangers-of-the-covid-19-vaccine/
Dr. Hotze Article: The So-Called COVID-19 “Vaccine” Is Really A Dangerous Experimental Gene Therapy – Just Say “No!”
https://www.hotzehwc.com/wp-content/uploads/2015/02/Covid-vaccine-flyer-corrected.pdf
Copy of Dr. Hotze’s Healthy Living Newsletter with article about COVID Vaccine